8-K: Applied Therapeutics Announces New Chief Medical Officer and Positive Long-Term Data for Govorestat in CMT-SORD Trial

Applied Therapeutics, Inc. has appointed Dr. Evan P. Bailey as its new Chief Medical Officer, succeeding Dr. Riccardo Perfetti, while also reporting mixed but promising long-term clinical results for its lead drug candidate, govorestat, in the INSPIRE Phase 2/3 trial for CMT-SORD Deficiency.

Summary

• Dr. Riccardo Perfetti departed his role as Chief Medical Officer (CMO) of Applied Therapeutics, Inc. effective June 15, 2025. His departure was not due to any dispute with the company.
• Dr. Evan P. Bailey, previously Senior Vice President, Clinical Development, was appointed to succeed Dr. Perfetti as Chief Medical Officer, effective June 15, 2025.
• Dottie Caplan was promoted to Executive Vice President, Patient Advocacy and Government Affairs.
• In the INSPIRE Phase 2/3 trial for Sorbitol Dehydrogenase (SORD) Deficiency, govorestat did not meet its primary endpoint, the 10-meter walk-run test (10MWRT) at 12 months (p = 0.7287).
• However, govorestat demonstrated statistically significant improvements on key secondary endpoints, including the CMT-Health Index (CMT-HI) at 12 months.
• Statistically significant correlations were observed between absolute reduction in sorbitol and changes in 10MWRT (p = 0.031) and the CMT-FOM Lower Limb domain (p = 0.038).
• Govorestat significantly lowered blood sorbitol levels (p < 0.001) and continued to be generally safe and well tolerated through 24 months of treatment.
• Topline 18-month and 24-month patient-level analyses showed slowing of disease progression via MRIs at 24 months, maintained improvements in outcomes (including CMT-HI), and sustained reduction in sorbitol levels.
• Dr. Perfetti will receive severance benefits including 12 months of his monthly base salary ($580,000 annually), his target annual bonus ($232,000), 12 months of health insurance premiums, and accelerated vesting of all unvested options and restricted stock units (RSUs).
• Dr. Bailey's new compensation includes an annual base salary of $585,000, eligibility for an annual performance-based incentive cash bonus with a target of 40% of his base salary ($234,000), and a grant of 300,000 restricted stock units (RSUs) vesting over four years.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the primary endpoint of the clinical trial was missed, which is a significant negative, the strong positive results from secondary endpoints, long-term data (18 and 24 months), MRI evidence of slowed disease progression, and sustained sorbitol reduction provide substantial optimism for the drug's potential. The leadership changes, particularly the appointment of an experienced internal candidate as CMO, are also positive for continuity and strategic execution. The overall picture is mixed but leans positive due to the comprehensive efficacy and safety data beyond the primary endpoint.

Positives

• Appointment of Dr. Evan P. Bailey as CMO brings significant experience in clinical development and successful drug launches (e.g., TRIKAFTA for CF).
• Promotion of Dottie Caplan strengthens patient advocacy and government affairs, integrating patient voice into development strategy.
• Govorestat demonstrated statistically significant improvements on the key secondary endpoint, CMT-Health Index (CMT-HI), at 12 months.
• Statistically significant lowering of blood sorbitol levels (p < 0.001) was observed, indicating the drug's mechanism of action is effective.
• Positive long-term data (18 and 24 months) showed maintained improvements in outcomes, including CMT-HI, and sustained reduction in sorbitol.
• MRIs at 24 months demonstrated slowing of disease progression in patients treated with govorestat, a significant objective measure.
• Govorestat continued to be generally safe and well tolerated through 24 months of treatment, with similar adverse event incidence between active and placebo groups.

Negatives

• The primary endpoint of the INSPIRE Phase 2/3 trial, the 10-meter walk-run test (10MWRT) at 12 months, was not statistically significant (p = 0.7287). This is a critical factor for regulatory approval.
• The 10MWRT was removed from the CMT-FOM composite score since the study initiation, which might complicate interpretation or regulatory discussions regarding the primary endpoint's relevance.

Risks

• Actual results could differ materially and adversely from forward-looking statements due to various risks and uncertainties.
• Risks regarding the Company's business are described in detail in its SEC filings, including the Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
• The Company's ability to obtain and timing of regulatory approval of its current and future product candidates is uncertain.
• The potential benefits, efficacy, safety, and tolerability of govorestat may not be fully realized.
• The potential market opportunity for govorestat may not be as anticipated.
• The Company's ability to fund working capital requirements and sufficiency of capital resources are subject to risks.
• Intellectual property position and duration of patent rights are subject to risks.
• Developments or disputes concerning intellectual property or other proprietary rights could occur.
• Government and third-party payor coverage and reimbursement are uncertain.
• Ability to compete in the markets served is a risk.
• Impact of government laws and regulations and liabilities thereunder could be adverse.
• Developments relating to competitors and the industry could impact the company.
• Ability to achieve anticipated benefits from partnerships (e.g., Advanz Pharma) is not guaranteed.

Future Outlook

The company's future outlook includes advancing its strategy, business plans, and focus, including the announced leadership transition. It also involves continued progress, timing, and expectations regarding the clinical development of govorestat, assessing its potential benefits, efficacy, safety, tolerability, and market opportunity. The company also anticipates future meetings, interactions, or submissions with regulatory authorities, including the U.S. Food and Drug Administration, regarding its product candidates.

Management Comments

• "We are pleased to appoint Evan as our next CMO, and Dottie as our EVP, Patient Advocacy and Government Affairs." John H. Johnson, Executive Chairman of Applied Therapeutics.
• "Evan has played a fundamental role in progressing our development programs since joining Applied four years ago. His experience in clinical development execution, including all aspects of both early and late-stage development, will be critical to our efforts to bring our potential treatments for rare diseases to market." John H. Johnson, Executive Chairman of Applied Therapeutics.
• "Dottie has been instrumental in implementing the patient voice into our clinical development strategy and serving our patient communities, and we are excited for her to continue to lead Applied's advocacy efforts in this new role." John H. Johnson, Executive Chairman of Applied Therapeutics.
• "On behalf of the management team and Board of Directors, I thank Riccardo for his many years of dedicated service to Applied and we wish him the best." John H. Johnson, Executive Chairman of Applied Therapeutics.
• "I am honored to step into the role of CMO. Advancing novel drug candidates for the potential treatment of indications with high unmet medical needs has been a long-standing passion of mine, and I'm committed to further advancing our portfolio of supporting data for govorestat with the goal of ultimately bringing our transformative treatments to the many rare disease patients in need." Dr. Evan P. Bailey, CMO.
• "I believe in the promise of govorestat and its ability to address the mechanistic underlying drivers of both Classic Galactosemia and CMT-SORD." Dr. Evan P. Bailey, CMO.
• "As a practicing pediatrician, I see firsthand just how important this innovation and dedication is. In this new role, I look forward to continuing to work closely with our clinical collaborators, patient advocacy groups, regulators and the patients and their caregivers involved in our clinical trials." Dr. Evan P. Bailey, CMO.
• "It has been a privilege to serve as Applied's CMO." Dr. Riccardo Perfetti.
• "I am immensely proud of the team for their relentless drive to bring the candidates in our pipeline to the patients who need them, and I have no doubt that Evan will be instrumental in advancing govorestat and helping Applied achieve its clinical goals." Dr. Riccardo Perfetti.
• "Advocating for patients has always been at the heart of my work, and it's been a privilege to help elevate their voices in ways that matter." Ms. Dottie Caplan, EVP, Patient Advocacy and Government Affairs.
• "As I expand my role at Applied to include government affairs, I'm looking forward to deepening our engagement with policymakers to help shape policies that reflect the real needs of the rare disease communities we serve. I'm excited to continue to champion the potential of govorestat for the many patients with rare diseases, specifically Galactosemia, CMT-SORD and PMM2-CDG." Ms. Dottie Caplan, EVP, Patient Advocacy and Government Affairs.

Industry Context

This announcement highlights a common strategic move in the biopharmaceutical industry: adjusting executive leadership to align with ongoing clinical development priorities. The promotion of an internal candidate to CMO, especially one with a strong background in clinical development and prior successful drug launches, suggests a focus on execution and commercialization readiness for govorestat. The emphasis on patient advocacy and government affairs also reflects a growing trend in rare disease drug development, where patient voice and policy engagement are crucial for market access and adoption. The mixed clinical trial results for govorestat, where a primary endpoint was missed but secondary and long-term data show promise, are typical challenges in drug development, particularly for rare diseases where endpoints can be complex and patient populations small. The continued focus on govorestat for multiple CNS rare metabolic diseases (Classic Galactosemia, CMT-SORD, PMM2-CDG) indicates a pipeline strategy centered around a single, versatile lead candidate.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks. Clinical trial outcomes for rare diseases like CMT-SORD are often unique due to the specific patient populations and disease mechanisms, making direct comparisons challenging without more context on similar programs or approved therapies.

Management Changes

Stakeholder Impact

• **Shareholders:** Impacted by leadership changes and clinical trial results, which could influence stock price. The mixed trial results (missed primary endpoint but strong secondary/long-term data) create uncertainty but also potential for future value if regulatory path is cleared.
• **Employees:** Dr. Bailey's promotion and Ms. Caplan's expanded role indicate internal growth opportunities. Dr. Perfetti's departure with a severance package suggests a standard, non-contentious transition.
• **Patients and Caregivers (CMT-SORD):** The clinical trial results for govorestat offer hope for a new treatment, especially with positive long-term data on disease progression and quality of life, despite the missed primary endpoint. Continued engagement with patient advocacy groups is highlighted.
• **Regulatory Authorities (e.g., FDA):** The company will engage with regulatory bodies regarding govorestat's approval, particularly in light of the primary endpoint not being met but strong secondary and long-term data being available. The change in the 10MWRT's status in the CMT-FOM composite score might be a point of discussion.
• **Investment Professionals:** The detailed clinical data and leadership changes provide critical information for evaluating the company's pipeline and strategic direction.

Next Steps

• Further advancement of the portfolio of supporting data for govorestat.
• Continued work with clinical collaborators, patient advocacy groups, regulators, and patients/caregivers involved in clinical trials.
• Potential meetings, interactions, or submissions with regulatory authorities, including the U.S. Food and Drug Administration, regarding product candidates.
• Dr. Perfetti will remain available to the Company to help ensure a smooth transition.
• Dr. Bailey will be eligible to receive an annual grant of equity awards commencing with the 2026 calendar year.

Key Dates

Recommendation

Keywords

Applied Therapeutics, APLT, Govorestat, CMT-SORD Deficiency, Charcot-Marie-Tooth disease, Rare disease, Clinical trial results, Phase 2/3 INSPIRE trial, Chief Medical Officer, Executive leadership, Biopharmaceutical, Aldose Reductase Inhibitor, Sorbitol Dehydrogenase, Patient advocacy, Corporate governance, SEC filing, Form 8-K